Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
luvesilocin
- Development stage
- Phase 1
- Lead developer
- Reunion Neuroscience
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Luvesilocin is a synthetic tryptamine prodrug designed for rapid-acting antidepressant effects with a shorter psychoactive duration than traditional psychedelics. Developed by Reunion Neuroscience, it is a prodrug of 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT). The molecule acts as a non-selective serotonin receptor agonist, primarily targeting the 5-HT2A receptor to induce neuroplasticity and therapeutic psychological effects. It is administered via subcutaneous injection and is currently being evaluated in Phase 2 clinical trials for postpartum depression (PPD), where it has received FDA Breakthrough Therapy Designation. Its design aims for a clinical experience lasting approximately 3.6 hours, facilitating easier integration into standard clinical practice compared to psilocybin.
- Other names
- 4-glutaryloxy-N,N-diisopropyltryptamine4-HO-DiPT O-glutarate4-GO-DiPT
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)
Beyond the preview
Go deeper on luvesilocin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on luvesilocin.